None (healthy subjects)
Conditions
Interventions
Group 1: Single oral intake of drinking solution HV 1058-1. Volume containing 50g glycaemic carbohydrates.
Group 2: Oral intake of a glucose solution (50g glucose). Intake 3 times on 3 different days.
Sponsors
Fresenius Kabi Deutschland GmbH
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Healthy subjects who give informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Aged 60 years/ Pregnant or lactating/ Body mass index (BMI) = 30kg/m2/ History of diabetes mellitus or fasting blood glucose value > 6.1 mmol/l/ Any known food allergy or intolerance/ Medical condition(s) or medication(s) known to affect glucose regulation or appetite and/or influence digestion and absorption of nutrients/ Use steroids, protease inhibitors, amphetamines or antipsychotics/ Use of medications known to affect glucose tolerance (excluding oral contraceptives)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of glycaemic index by comparing the blood sugar level enhancement after intake of the test product or a glucose solution within 2 hours after intake. Blood sugar measurement is done -5 and 0 minutes before and 15, 30, 45, 60, 90 and 120 minutes after intake. The blood sugar level measurement is done spectrophotometrically. | — |
Countries
United Kingdom
Contacts
Public ContactSteffen Benzing
Fresenius Kabi Deutschland GmbH
Outcome results
None listed